FINE FOODS+ PHARMACEUTICALS financials
FINE FOODS+ PHARMACEUTICALS
8156009111DEE8553765 ISIN: IT0005215329 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €253.5M | €245.1M |
| Operating expenses | €237.0M | €230.4M |
| Employee benefits expense | €52.5M | €47.6M |
| Depreciation & amortisation | €18.0M | €15.8M |
| Operating profit (EBIT) | €16.4M | €14.6M |
| Finance costs | €3.0M | €3.5M |
| Profit before tax | €13.6M | €11.8M |
| Income tax expense | €3.5M | €3.7M |
| Profit for the year | €10.1M | €8.2M |
| Total comprehensive income | €10.2M | €8.2M |
| Per share | ||
| Basic EPS | €0.41 | €0.33 |
| Diluted EPS | €0.41 | €0.33 |
| Free cash flow / share | €-0.12 | €0.48 |
| Cash flow statement | ||
| Net cash from operating activities | €31.8M | €45.9M |
| Net cash from investing activities | -€35.8M | -€31.6M |
| Purchase of PP&E (capex) | €34.6M | €33.9M |
| Purchase of intangibles | €1.4M | €838.3K |
| Net cash from financing activities | €23.8M | -€14.1M |
| Dividends paid | €3.4M | €2.9M |
| Proceeds from borrowings | €71.6M | €1.5M |
| Repayments of borrowings | €39.5M | €12.1M |
| Lease liability payments | €363.5K | €417.0K |
| Balance sheet | ||
| Total assets | €280.0M | €242.6M |
| Non-current assets | €162.7M | €146.2M |
| Property, plant & equipment | €144.2M | €126.1M |
| Right-of-use assets | €2.9M | €2.9M |
| Intangible assets & goodwill | €11.5M | €11.5M |
| Current assets | €117.4M | €96.4M |
| Inventories | €35.0M | €31.9M |
| Trade & other receivables | €36.6M | €37.5M |
| Cash & equivalents | €38.9M | €19.2M |
| Total equity | €134.2M | €132.1M |
| Non-current liabilities | €78.6M | €39.9M |
| Long-term borrowings | €72.7M | €35.0M |
| Lease liabilities (non-current) | €899.7K | €847.5K |
| Current liabilities | €67.2M | €70.7M |
| Short-term borrowings | €12.8M | €18.4M |
| Lease liabilities (current) | €390.6K | €325.2K |
| Deferred tax liabilities | €303.8K | €284.0K |
| Derived metrics | ||
| Free cash flow | -€2.9M | €12.0M |
| Operating margin | 6.5% | 6.0% |
| Net margin | 4.0% | 3.3% |
| Return on equity | 7.5% | 6.2% |
| Cash conversion ratio | 3.15× | 5.62× |
| Capex coverage | 0.92× | 1.35× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€4.7M | €10.3M |
| Adjustments For Decrease Increase In Trade Account Receivable | €741.5K | €292.1K |
| Adjustments For Deferred Tax Expense | €1.7M | €2.8M |
| Adjustments For Depreciation Expense | €0 | €3.0K |
| Adjustments For Finance Costs | €3.8M | €3.4M |
| Adjustments For Finance Income | -€1.0M | -€699.7K |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -€61.9K | -€118.2K |
| Adjustments For Income Tax Expense | €1.9M | €952.3K |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | -€208.4K | -€106.8K |
| Adjustments For Increase Decrease In Trade Account Payable | -€203.2K | €4.2M |
| Adjustments For Provisions | €1.1M | €1.6M |
| Current Tax Assets Current | €47.4K | €18.0K |
| Current Tax Liabilities Current | €995.5K | €219.1K |
| Deferred Tax Assets | €1.9M | €3.5M |
| Equity and Liabilities | €280.0M | €242.6M |
| Finance Costs Paid Classified As Operating Activities | €42.3K | €59.0K |
| Finance Income | €200.8K | €699.7K |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €18.7K | €3.4K |
| Income Taxes Paid Refund Classified As Operating Activities | -€1.1M | -€1.3M |
| Increase Decrease In Cash and Cash Equivalents | €19.7M | €210.2K |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Transfer Between Revaluation Reserve and Retained Earnings | — | €0 |
| Intangible Assets Other Than Goodwill | €1.9M | €1.6M |
| Interest Paid Classified As Operating Activities | -€2.8M | -€2.7M |
| Issued Capital | €22.8M | €22.8M |
| Miscellaneous Other Operating Expense | €1.5M | €2.1M |
| Miscellaneous Other Operating Income | €1.4M | €1.3M |
| Noncurrent Provisions For Employee Benefits | €1.9M | €2.1M |
| Other Comprehensive Income | €59.1K | €10.9K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €77.7K | €14.3K |
| Other Current Assets | €6.9M | €7.8M |
| Other Current Liabilities | €16.8M | €15.2M |
| Other Longterm Provisions | €2.7M | €1.6M |
| Other Noncurrent Nonfinancial Assets | €324.1K | €597.9K |
| Other Reserves | €106.9M | €102.9M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €149.8K | €390.0K |
| Purchase of Treasury Shares | -€4.6M | -€118.3K |
| Reserve of Remeasurements of Defined Benefit Plans | €251.0K | €191.9K |
| Retained Earnings | €810.3K | €4.7M |
| Revenue From Contracts With Customers | €252.1M | €243.8M |
| Services Expense | €25.8M | €23.6M |
| Trade and Other Current Payables To Trade Suppliers | €36.4M | €36.6M |
Every line item above is a fact tagged in FINE FOODS+ PHARMACEUTICALS's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.